• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Lo Minastrin, (norethindrone acetate, ethinyl estradiol, ferrous fumarate)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Lo Minastrin, (norethindrone acetate, ethinyl estradiol, ferrous fumarate)

  • Profile

Profile

Contact Information

Currently Enrolling Trials

    Show More

    General Information

    Lo Minastrin Fe (norethindrone acetate and ethinyl estradiol chewable tablets, ethinyl estradiol tablets and ferrous fumarate tablets) is an estrogen/progestin combined oral contraceptive. It works primarily by suppressing ovulation. Other possible mechanisms may include cervical mucus changes that inhibit sperm penetration and endometrial changes that reduce the likelihood of implantation.

    Lo Minastrin Fe is specifically indicated for use by women to prevent pregnancy.

    Lo Minastrin is supplied as tablets for oral administration. Lo Minastrin Fe adminitration should begin on Day 1 of the menstrual cycle (that is, the first day of her menstrual bleeding). One blue tablet should be taken daily for 24 consecutive days, followed by one white tablet daily for 2 consecutive days, followed by one brown tablet daily for 2 consecutive days. To achieve maximum contraceptive effectiveness, Lo Minastrin Fe must be taken exactly as directed. The blue tablet should be chewed and swallowed. The patient should drink a full glass (8 ounces) of water immediately after chewing and swallowing the blue tablet. The white tablet and the brown tablet are swallowed.

    Clinical Results

    FDA Approval
    The FDA approval of Lo Minastrin FE was based on results from a clinical trial conducted with norethindrone acetate 1 mg/ethinyl estradiol 10 mcg tablets and ethinyl estradiol 10 mcg tablets. Lo Minastrin Fe is bioequivalent to these norethindrone acetate/ethinyl estradiol tablets and ethinyl estradiol tablets. In a one year (thirteen 28-day cycles) multicenter open-label clinical trial, 1,270 women 18 to 35 years of age, were studied to assess the efficacy of norethindrone acetate/ethinyl estradiol tablets and ethinyl estradiol tablets, completing the equivalent of 12,482 28-day evaluable cycles of exposure. The pregnancy rate (Pearl Index [PI]) in women 18 to 35 years of age was 2.92 pregnancies per 100 women-years of use, based on 28 pregnancies that occurred after the onset of treatment and extending through the 7 days following the last dose of norethindrone acetate/ethinyl estradiol tablets and ethinyl estradiol tablets. The PI includes women who did not take the pill correctly.

    Side Effects

    Adverse events associated with the use of Lo Minastrin Fe may include, but are not limited to, the following:

    • nausea/vomiting
    • headache
    • bleeding irregularities
    • dysmenorrhea
    • weight change
    • breast tenderness
    • acne
    • abdominal pain
    • anxiety
    • depression

    Literature References

    Lo Minastrin Fe (norethindrone acetate and ethinyl estradiol chewable tablets, ethinyl estradiol tablets and ferrous fumarate tablets) is an estrogen/progestin combined oral contraceptive. It works primarily by suppressing ovulation. Other possible mechanisms may include cervical mucus changes that inhibit sperm penetration and endometrial changes that reduce the likelihood of implantation.

    Additional Information

    For additional information regarding Lo Minastrin FE or contraception, please visit the Warner Chilcott web page.

    Approval Date: 2013-07-01
    Company Name: Warner Chilcott
    Back to Listings

    Upcoming Events

    • 26Jan

      Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

    • 27Jan

      Medical Device Clinical Trials in China: Latest Regulatory Developments

    • 11Feb

      Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

    • 23Mar

      Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

    • 26Apr

      MAGI's Clinical Research vConference — Spring 2021

    Featured Products

    • Regenerative Medicine – Steps to Accelerate Development : PDF

      Regenerative Medicine: Steps to Accelerate Development

    • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

      Clinical Trial Agreements: A Guide to Key Words and Phrases

    Featured Stories

    • TechInnovation-360x240.png

      Pace of Technology Innovation in Trials Could Slow After Pandemic Eases

    • AskTheExperts-360x240.png

      Ask the Experts: Certifying and Maintaining Copies of Original Source Documents

    • Resources-360x240.png

      Trial Complexity, Endpoints Continue to Increase, Stretching Site Resources

    • FocusinRed-360x240.png

      Return to Focus on Risk Management Postpandemic Could Prove Challenging to Sites

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell My Personal Information

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing